ESTER CERDEIRA SABINO

(Fonte: Lattes)
Índice h a partir de 2011
43
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Patologia, Faculdade de Medicina - Docente
LIM/46 - Laboratório de Parasitologia Médica, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Limpar filtros

Configurações

Autor: SABINO, E. C. ×

Resultados de Busca

Agora exibindo 1 - 10 de 45
  • conferenceObject
    Symptoms and Outcomes of Dengue Among Transfusion Recipients in Brazil Who Were RNA plus or Who Received an RNA plus unit Compared to RNA- Recipients
    (2014) SABINO, E. C.; OLIVEIRA, C. D.; LOUREIRO, P.; LOPES, M.; CAPUANI, L. D.; MCCLURE, C.; CHOWDHURY, D.; KLEINMAN, S.; BUSCH, M.; CUSTER, B.
  • conferenceObject
    Benznidazole treatment is associated with Trypanosoma cruzi blood PCR negativity and less cardiac lesions in Chagas disease: NIH SaMitrop Study
    (2017) CARDOSO, C. S.; SABINO, E. C.; OLIVEIRA, C. D. L.; OLIVEIRA, L. C.; FERREIRA, A. M.; BIERRENBACH, A. L.; SILVA, J. L. P.; COLOSIMO, E. A.; CUNHA-NETO, E.; RIBEIRO, A. L. P.
  • conferenceObject
    Whole exome sequencing of Chagas disease cardiomyopathy families reveals accumulation of rare variants in mitochondrial and inflammation-associated genes
    (2019) CUNHA-NETO, E.; MARQUET, S.; FRADE, A. Farage; FERREIRA, A. Mota; OUARHACHE, M.; IANNI, B.; FERREIRA, L. Rodrigues Pinto; RIGAUD, V. Oliveira-Carvalho; ALMEIDA, R. Ribeiro; CANDIDO, D.; TORRES, M.; GALLARDO, F.; FERNANDES, R.; MADY, C.; BUCK, P.; CARDOSO, C.; SANTOS-JUNIOR, O. R.; OLIVEIRA, L. C.; OLIVEIRA, C. D. L.; NUNES, M. do Carmo; ABEL, L.; KALIL, J.; RIBEIRO, A. L. P.; SABINO, E. C.; CHEVILLARD, C.
  • conferenceObject
    Motivation to Donate Among Granulocytes, Apheresis, and Whole Blood Donors in a Brazilian Blood Center
    (2013) ROCHA, P. C.; SABINO, E. C.; OLIVEIRA, C. D.; PATAVINO, G. M.; CAPUANI, L. D.; ALMEIDA-NETO, C. de
  • article 9 Citação(ões) na Scopus
    Blood donation in a large urban centre of southeast Brazil: a population-based study
    (2016) MORENO, E. C.; BOLINA-SANTOS, E.; MENDES-OLIVEIRA, F.; MIRANDA, C.; SABINO, E. C.; CIOFFI, J. G. M.; CAMARGOS, V.; CAIAFFA, W.; XAVIER, C. C.; PROIETTI, F. A.; CARNEIRO-PROIETTI, A. B. de Freitas
    ObjectivesThis study aimed to estimate the prevalence and characterise potential blood donors and non-donors in a well-populated and representative urban area of Southeastern Brazil. BackgroundStudies on blood donation usually evaluate individuals who donate. Population-based studies may contribute to characterise those who never reach the blood centre, trying to increase the range of donors. Study Design and MethodsThis was a secondary analysis of a population-based survey and a blood donor motivation study [Recipient Epidemiology and Donor Evaluation study (REDS II) International]. In a cross-sectional study 4047 individuals representing a metropolitan area answered the question Have you ever donated blood at least once in your life?'. The profiles (Yes/No') were compared. Non-donors from this reference population were compared with donors of a local blood center, in a case control analysis. ResultsA total of 690% of the population had never donated blood and was composed mostly of women, younger than 30 years old, people not contributing to social security and not subscribing to newspapers. In the case-control study, the likelihood of donating was higher for: men, younger than 50 years old, longer time of education, married, participating in political campaigns and with a good self-perception of health. The factors associated with no blood donation were: self-reported mixed or white race/ethnicity, income higher than two minimum wages and belonging to trade union, political, religious/spiritual, or other social group and worse self perception of health. ConclusionsThis population-based study allowed us to characterise a high proportion of people that never reaches the blood centre. The results may be used to diversify the donor profile, creating strategies to target those least likely to donate blood, as women, white people and those with higher income and purchasing power.
  • conferenceObject
    T. cruzi PCR Positivity is Associated with Clinical and Laboratory Markers of Severity of Chagas Cardiomyopathy
    (2012) SABINO, E. C.; RIBEIRO, A. L.; LEE, T.; KEATING, S. M.; CARRICK, D. M.; DENG, X.; OLIVEIRA, C. D.; KAVOUNIS, K.; CUSTER, B.; BUSCH, M. P.
  • conferenceObject
    Incidence of Chagas Cardiomyopathy and Relative Diagnostic Value of Electrocardiogram (ECG) Versus Echocardiogram (ECHO) Among T. cruzi Seropositive Donors
    (2012) SABINO, E. C.; RIBEIRO, A.; PATAVINO, G. M.; CAPUANI, L. D.; ALMEIDA-NETO, C. de; OLIVEIRA, C. Di Lorenzo; CARRICK, D. M.; CUSTER, B.; BUSCH, M. P.; MURPHY, E. L.
    Background/Case Studies: Few studies have prospectively evaluated the natural history of Chagas cardiomyopathy, including disease penetrance, prognostic factors and indications for treatment. Nor has the diagnostic utility of ECHO been compared to the simpler and less costly ECG screening. Study Design/Methods: In a retrospective cohort study, T. cruzi seropositive blood donors with an index blood donation in 1996-2002 in Sao Paulo and Montes Claros, Brazil were matched to seronegative donors on index donation date, age, gender and city. 101 Chagas cardiomyopathy patients served as positive controls. In 2009-2010, all subjects underwent a health history questionnaire, medical examination, standardized ECG and ECHO. Subjects with abnormal screening EKG or ECHO were referred to a blinded panel of 3 cardiologists who adjudicated the outcome of Chagas cardiomyopathy. Diagnostic sensitivity, specifi city, positive predictive value (PPV) and negative predictive value (NPV) were calculated separately for ECHO and ECG. Results/Findings: Mean follow-up time was 10.5 years for the sero-positives and 11.1 years for the seronegatives. The sensitivity of the combined ECHO/ECG and expert panel algorithm was 98%, based on diagnoses of cardiomyopathy in 99 of 101 previously diagnosed Chagas cardiomyopathy patients, of whom 1 (1%) expert referral was triggered by ECHO alone, none by ECG alone and 98 (99%) by both ECHO and ECG. In contrast, 24 (5%) of 488 T. cruzi-seronegative control donors were falsely classifi ed as having Chagas cardiomyopathy (specifi city = 95%). Among the 499 T. cruzi seropositives, 315 (63%) were referred to the expert panel and 120 (24%) had defi nite Chagas-like cardiomyopathy, leading to an incidence difference of 1.85 per 100 person-years attributable to T. cruzi infection. The Table summarizes the sensitivity, specifi city and predictive values of ECHO and ECG screening for cardiomyopathy diagnosis among the T. cruzi seropositive individuals. Conclusion: There is a substantial (~2%) annual incidence of Chagas cardiomyopathy among initially asymptomatic T. cruzi seropositive blood donors. Among seropositives, ECG had better sensitivity and ECHO had better specifi city. Both tests had poor positive predictive value, but ECG had better negative predictive value. Future studies could use a two-step algorithm in which ECG is used to exclude those with a negative test and low likelihood of disease. ECHO would be done to refine the diagnosis only in patients with abnormal ECG fi ndings. Disclosure of Commercial Conflict of Interest M. P. Busch: NIH, Grants or Research Support; Novartis/Gen-Probe, Grants or Research Support; Terumo/Caridian, Grants or Research Support; Gen-Probe, Consulting or Board of Director Fees; Johnson & Johnson/Merck, Ortho, Consulting or Board of Director Fees; Abbott, Travel Support or Honorarium; Novartis, Travel Support or Honorarium; L. D. Capuani: Nothing to disclose; D. M. Carrick: Nothing to disclose; B. Custer: Nothing to disclose; C. de Almeida-Neto: Nothing to disclose; C. Di Lorenzo Oliveira: No Answer; E. L. Murphy: Nothing to disclose; G. M. Patavino: Nothing to disclose; A. Ribeiro: Nothing to disclose; E. C. Sabino: Nothing to disclose Disclosure of Grants Conflict of Interest M. P. Busch: Novartis, Grants or Research Support; Ortho, Grants or Research Support; Terumo/Caridian, Grants or Research Support; L. D. Capuani: Nothing to disclose; D. M. Carrick: Nothing to disclose; B. Custer: Nothing to disclose; C. de Almeida-Neto: Nothing to disclose; C. Di Lorenzo Oliveira: No Answer; E. L. Murphy: Nothing to disclose; G. M. Patavino: Nothing to disclose; A. Ribeiro: Nothing to disclose; E. C. Sabino: Nothing to disclose Expert Panel Diagnosis of Cardiomyopathy in T. cruzi seropositives ECHO YES (N = 120) NO (N = 379) Triggered by ECHO 75 77 PPV = 49% Not Triggered by ECHO 45 302 NPV = 87% Sens = 63% Spec = 80% ECG Triggered by ECG 114 151 PPV = 43% Not Triggered by ECG 6 228 NPV = 97% Sens = 95% Spec = 60%
  • conferenceObject
    Detection of human norovirus using next generation sequencing: Strain diversity and expanding whole-genome sequences availability from Brazil
    (2020) TINKER, R.; COSTA, A. C. Da; LEAL, E.; TAHMASEBI, R.; MILAGRES, F.; BRUSTULIN, R.; TELES, M. D. A. R.; LOBATO, M. C. A. B. S.; CHAGAS, R. T. Das; ABRAO, M. D. F. N. D. S.; SOARES, C. V. D. D. A.; DENG, X.; DELWART, E.; SABINO, E. C.; LUCHS, A.
  • article 21 Citação(ões) na Scopus
    Investigation of human parvovirus B19 occurrence and genetic variability in different leukaemia entities
    (2013) COSTA, A. C. da; BENDIT, I.; OLIVEIRA, A. C. S. de; KALLAS, E. G.; SABINO, E. C.; SANABANI, S. S.
    Human parvovirus B19V (B19V) has been associated with various haematological disorders, but data on its prevalence in leukaemia are scarce. In this cross-sectional study, we investigated patients in Sao Paulo, Brazil with leukaemia to determine the molecular frequency of B19 variants and characterize the viral genetic variability by partial and complete sequencing of the coding of non-structural protein 1 (NS1)/viral capsid proteins 1 and 2 (VP1/VP2). The presence of B19V infections was investigated by PCR amplification of the viral NS1 gene fragment and confirmed by sequencing analysis. The NS1/VP1/VP2 and partially larger gene fragments of the NS1-positive samples were determined by overlapping nested PCR and direct sequencing results. The B19V NS1 was detected in 40 (16%) of 249 bone marrow samples including 12/78 (15.4%) acute lymphoblastic leukaemia, 25/155 (16.1%) acute myeloid leukaemia and 3/16 (18.7%) chronic myeloid leukaemia samples. Of the 40 participants, 25 (62.5%) were infected with genotype 1a and 15 (37.5%) with genotype 3b. The phylogenetic analysis of other regions revealed that 12/40 (30%) of the patients with leukaemia were co-infected with genotypes 1a and 3b. In addition, a new B19V intergenotypic recombinant (1a/3b) and an NS1 non-recombinant genotype 1a were detected in one patient. Our findings demonstrated a relatively high prevalence of B19V monoinfections and dual infections and provide, for the first time, evidence of inter-genotypic recombination in adults with leukaemia that may contribute to the genetic diversity of B19V and may also be a source of new emerging viral strains with future implications for diagnosis, therapy and efficient vaccine development.
  • article 393 Citação(ões) na Scopus
    Establishment and cryptic transmission of Zika virus in Brazil and the Americas
    (2017) FARIA, N. R.; QUICK, J.; CLARO, I. M.; THEZE, J.; JESUS, J. G. de; GIOVANETTI, M.; KRAEMER, M. U. G.; HILL, S. C.; BLACK, A.; COSTA, A. C. da; FRANCO, L. C.; SILVA, S. P.; WU, C. -H.; RAGHWANI, J.; CAUCHEMEZ, S.; PLESSIS, L. du; VEROTTI, M. P.; OLIVEIRA, W. K. de; CARMO, E. H.; COELHO, G. E.; SANTELLI, A. C. F. S.; VINHAL, L. C.; HENRIQUES, C. M.; SIMPSON, J. T.; LOOSE, M.; ANDERSEN, K. G.; GRUBAUGH, N. D.; SOMASEKAR, S.; CHIU, C. Y.; MUNOZ-MEDINA, J. E.; GONZALEZ-BONILLA, C. R.; ARIAS, C. F.; LEWIS-XIMENEZ, L. L.; BAYLIS, S. A.; CHIEPPE, A. O.; AGUIAR, S. F.; FERNANDES, C. A.; LEMOS, P. S.; NASCIMENTO, B. L. S.; MONTEIRO, H. A. O.; SIQUEIRA, I. C.; QUEIROZ, M. G. de; SOUZA, T. R. de; BEZERRA, J. F.; LEMOS, M. R.; PEREIRA, G. F.; LOUDAL, D.; MOURA, L. C.; DHALIA, R.; FRANCA, R. F.; MAGALHAES, T.; MARQUES JR., E. T.; JAENISCH, T.; WALLAU, G. L.; LIMA, M. C. de; NASCIMENTO, V.; CERQUEIRA, E. M. de; LIMA, M. M. de; MASCARENHAS, D. L.; MOURA NETO, J. P.; LEVIN, A. S.; TOZETTO-MENDOZA, T. R.; FONSECA, S. N.; MENDES-CORREA, M. C.; MILAGRES, F. P.; SEGURADO, A.; HOLMES, E. C.; RAMBAUT, A.; BEDFORD, T.; NUNES, M. R. T.; SABINO, E. C.; ALCANTARA, L. C. J.; LOMAN, N. J.; PYBUS, O. G.
    Transmission of Zika virus (ZIKV) in the Americas was first confirmed in May 2015 in northeast Brazil(1). Brazil has had the highest number of reported ZIKV cases worldwide (more than 200,000 by 24 December 20162) and the most cases associated with microcephaly and other birth defects (2,366 confirmed by 31 December 20162). Since the initial detection of ZIKV in Brazil, more than 45 countries in the Americas have reported local ZIKV transmission, with 24 of these reporting severe ZIKV-associated disease(3). However, the origin and epidemic history of ZIKV in Brazil and the Americas remain poorly understood, despite the value of this information for interpreting observed trends in reported microcephaly. Here we address this issue by generating 54 complete or partial ZIKV genomes, mostly from Brazil, and reporting data generated by a mobile genomics laboratory that travelled across northeast Brazil in 2016. One sequence represents the earliest confirmed ZIKV infection in Brazil. Analyses of viral genomes with ecological and epidemiological data yield an estimate that ZIKV was present in northeast Brazil by February 2014 and is likely to have disseminated from there, nationally and internationally, before the first detection of ZIKV in the Americas. Estimated dates for the international spread of ZIKV from Brazil indicate the duration of pre-detection cryptic transmission in recipient regions. The role of northeast Brazil in the establishment of ZIKV in the Americas is further supported by geographic analysis of ZIKV transmission potential and by estimates of the basic reproduction number of the virus.